Company: MDCXW
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001062993-25-007073
Chunk: 208

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-04
Form: POS AM
Chunk 208
---
3.92 |     |            2.63 |
| Unvested at December 31, 2024    |     |   310,000 |   |     |           3.72 |     |             4.94 |     |            0.23 |

The weighted average grant-date fair value of options granted during the years ended December 31, 2024 and December 31, 2023 was C$2.82 and C$0.73, respectively. The weighted average grant-date fair value of options forfeited during the year ended December 31, 2024 was C$2.36. As of December 31, 2024 and December 31, 2023, there were $565,986 and $335,812 of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average period of 2.25 and 4.82 years, respectively. For the years ended December 31, 2024 and 2023, stock-based compensation expense was $713,119 and $98,585, respectively. Stock-based compensation expense has been reported in the Company's consolidated statements of operations and comprehensive loss within the line items 'general and administrative' and 'research and development' expenses. The following table presents the assumptions that were used in the Black-Scholes option pricing model to determine the fair value of share options granted during the period:

|                          |     |          2024 |     |    2023 |
| Expected dividend yield  |     |             - |     |       - |
| Risk-free interest rate  |     | 2.95% - 4.24% |     |   4.24% |
| Expected term (in years) |     |       5 years |     | 5 years |
| Expected volatility      |     |    95% - 100% |     |  93.10% |

The expected volatility is based on the share price volatility observed for comparable publicly traded companies over a period similar to the life of the options. The expected option life represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government bonds with a remaining term equal to the expected life of the options.

F-18 Medicus Pharma Ltd.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2024 and 2023
[expressed